TME Pharma N.V. (ENXTPA: ALTME)
Health Care · Biotechnology · DE
€0.11
-3.83% today · +14.9% 1Y
TME Pharma N.V. (ENXTPA: ALTME) operates in the Biotechnology industry within the Health Care sector. The company is valued at $11.64M and employs 12 people.
Over the last twelve months the share price has gained 14.9%, trading between 0.05 and 0.17.
Tweenvest scores TME Pharma N.V. across four factors: quality 12/100, value 91/100. Its strongest factor is value.
ALTME price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $11.64M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.03
- Dividend yield
- —
- Beta (5Y)
- 0.82
- 52-week high
- €0.17
- 52-week low
- €0.05
- Avg volume (3M)
- —
- Shares outstanding
- 94.09M
- Employees
- 12
- Next earnings
- —
About TME Pharma N.V.
TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.
- ISIN
- NL0015000YE1
- Founded
- 1997
- Listed since
- Sep 30, 2016
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| NextCell Pharma ABOM: NXTCL | $12.20M | Skr0.96 | -5.53% |
| Radiopharm Theranostics LimitedASX: RAD | $12.07M | AU$0.00 | -20.00% |
| Pharmala Biotech Holdings Inc.CNSX: MDMA | $12.02M | CA$0.16 | -27.91% |
| EOM Pharmaceuticals Holdings, Inc.OTCPK: IMUC | $12.02M | $0.10 | -40.21% |
| AEON Biopharma, Inc.NYSEAM: AEON | $11.57M | $0.23 | -15.94% |
| BioLineRx Ltd.TASE: BLRX | $11.56M | ₪0.01 | -7.69% |
| Eagle Pharmaceuticals, Inc.OTCPK: EGRX | $11.53M | $0.89 | -8.76% |
| Aelis Farma SAENXTPA: AELIS | $11.50M | €0.75 | -5.88% |
Figures last refreshed Oct 18, 2026.